- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02519361
Involvement of the Translation Initiation Factors in Resolution of Inflammation in the Elderly Population
The Involvement of the Translation Initiation Factors eIF4E and eIF4G in Resolution of Inflammation in the Elderly Population
Aging cause specific changes in the immune system. Processes like "immunoessence" and "inflammaging" offend the functioning of the immune cells and expose the elderly patient to infections that can lead to morbidity and death.
Protein translation regulation offers a strategic advantage to the immune cells, because it enables rapid activation or termination of synthesis of specific proteins, required for inflammation or its resolution. Translation initiation depends on recruitment of eukaryotic initiation factor "eIF4F" complex.
The aim of the current study is to investigate the involvement of the translation initiation factors (eIF4E and eIF4G) in the process of recovery from acute infection in elderly patient admitted to the internal department with an acute infection.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
- Blood samples of elderly patients diagnosed with acute infection (fever and leukocytosis) will be collected twice - at admittance to Meir hospital and after recovery (24-48 hours without fever and leukocytosis). evidence of infection (chest x ray, urine and blood samples) will be collected. participants will be divided to two age groups: 65-80 yrs and very old patient >85 yrs, and will be compared to younger patients aged 50-65.
- Peripheral blood samples will be separated to subpopulations of lymphocytes, monocytes and polymorphonuclears, and protein will be extracted.
- protein lysates will be separated by SDS-PAGE electrophoresis and immunoblotted for phosphorylated and total eIF4E and eIF4G; their regulators: Mnk 1/2, 4EBP1, mTOR and targets: cyclin D1, c-Myc, survivin, BCL2, VEGFA, etc.
- Paired samples (within each age group) will be analyzed and correlated with clinical response of the patients. The source of the infection will also be considered.
- Comparison between age groups at admittance and upon recovery will be made (Unpaired).
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- patient aged 50 y and more with:
- fever >38c that started in the 48 hours prior to admission
- leukocytosis >10.0 K/microLiter
- suspected source of infection by symptoms, lab results or imaging
- treatment with antibiotics started in the last 24 hours or is about to be started
Exclusion Criteria:
- patients who cannot sign the informed concent ( dementia)
- patients with active malignancy
- patients who are under chemotherapy
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Translation initiation factors expression by immunoblotting, in leukocytes sub population
Tidsram: 1 week
|
Assessment of eIF4E and eIF4G expression by immunoblotting, in leukocytes sub populations under inflamed conditions and upon resolution of acute inflammation, in three groups of age
|
1 week
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Translation initiation factors regulators expression by immunoblotting in leukocytes sub population
Tidsram: 1 week
|
Assessment of eIF4E and eIF4G regulators expression by immunoblotting, in leukocytes sub populations under inflamed conditions and upon resolution of acute inflammation in three age groups
|
1 week
|
|
Translation initiation factors targets expression by immunoblotting in leukocytes sub population
Tidsram: 1 week
|
Assessment of eIF4E and eIF4G targets expression by immunoblotting in leukocytes sub populations under inflamed conditions and upon resolution of acute inflammation, in three age groups
|
1 week
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Rachel Heffez Ayzenfeld, MD, r.h.ayzenfeld
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 0148-15-MMC
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .